Background/Purpose
We previously reported perioperative and oncologic outcomes of robot‐assisted pancreatoduodenectomy (RAPD); however, the follow‐up period in RAPD was relatively short, and disease‐matched survival analyses were lacking. Therefore, this study investigated time trends of perioperative and long‐term disease‐matched outcomes of RAPD.
Methods
Annual clinicopathologic outcomes of 328 patients with RAPD between 2015 and 2020 were analyzed and compared with 929 patients with open PD using the propensity score‐matched (PSM) analysis based on postoperative pancreatic fistula (POPF) risk and oncologic variables in malignant patients.
Results
Robot‐assisted pancreatoduodenectomy cases increased from 10 (6.3%) in 2015 to 116 (50.2% of total PD) in 2020, with malignancy proportion increasing from 50.0% to 80.2%. POPF risk‐based PSM analysis showed that compared with open PD, RAPD had younger patients (63.7 vs 65.6 years, P = .018), longer operation time (339.1 vs 290.0 min, P < .001); however, estimated blood loss (P = .275), complications (17.1% vs 18.3%, P = .702), and clinically relevant POPF (9.8% vs 11.1%, P = .584) were similar with shorter postoperative hospital stay (10.8 vs 15.6 days, P < .001). In disease and stage‐matched malignant patients, R0 resection (93.9% vs 91.2%, P = .376), total retrieved lymph node (18.2 vs 19.9, P = .058), and 5‐year survival rate (57.3% vs 60.6%, P = .406) were similar between RAPD and open PD, also in pancreatic cancer patients (31.6% vs 26.3%, P = .068).
Conclusions
Robot‐assisted pancreatoduodenectomy demonstrated similar perioperative outcomes with earlier recovery and equivalent long‐term survival with open PD. RAPD is safe and feasible for periampullary lesions, including pancreatic cancers, and its role will expand in the era of minimally invasive surgery.